Cancer cachexia: A therapeutic approach
- 1 January 2000
- journal article
- review article
- Published by Wiley in Medicinal Research Reviews
- Vol. 21 (1) , 83-101
- https://doi.org/10.1002/1098-1128(200101)21:1<83::aid-med4>3.0.co;2-1
Abstract
Cancer cachexia is a complex syndrome which occurs in more than two-thirds of patients who die with advanced cancer. The main components of this pathological state are anorexia and metabolic abnormalities such as glucose intolerance, fat depletion, and muscle protein catabolism among others. The aim of the present study is to review the different therapeutic approaches that have been designed to fight and counteract cancer cachexia.Keywords
This publication has 95 references indexed in Scilit:
- The metabolic basis of cancer cachexiaMedicinal Research Reviews, 1997
- Effect of medroxyprogesterone acetate on the quality of life of the oncologic patientAnti-Cancer Drugs, 1997
- Medroxyprogesterone acetate reduces the in vitro production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patientsEuropean Journal Of Cancer, 1997
- Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrationsEuropean Journal of Pharmacology, 1994
- The role of cytokines in muscle wasting: Its relation with cancer cachexiaMedicinal Research Reviews, 1992
- Nutritional Support and Cancer CachexiaHematology/Oncology Clinics of North America, 1991
- A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancerCancer, 1990
- Protein-calorie undernutrition in hospitalized cancer patientsThe American Journal of Medicine, 1980
- Nutritional assessment and patient outcome during oncological therapyCancer, 1979
- THE IMMEDIATE CAUSES OF DEATH IN CANCERThe Lancet Healthy Longevity, 1932